Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumours

Bookmark and Share
Published: 12 Nov 2013
Views: 4365
Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany

Dr Harshad Kulkarni talks to ecancer at the 2013 NCRI Cancer Conference in Liverpool about PET/CT on neuroendocrine tumours.

A German multi-institutional registry study found that this is an effective therapy for patients with G1-2 neuroendocrine tumours with a survival advantage of several years compared to other therapies and only minor side effects.

The concept of theranostics has now been translated to other malignancies such as prostate cancer.